Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis

American Journal of Gastroenterology

Volumn 105, Issue 8, 2010, Pages 1811-1819

  Jürgens, Matthias ^a   Laubender, Rüdiger P ^b   Hartl, Franziska ^a   Weidinger, Maria ^a   Seiderer, Julia ^a   Wagner, Johanna ^a   Wetzke, Martin ^c   Beigel, Florian ^a   Pfennig, Simone ^a   Stallhofer, Johannes ^a   Schnitzler, Fabian ^a   Tillack, Cornelia ^a   Lohse, Peter ^a   Göke, Burkhard ^a   Glas, Jürgen ^a,b,d   Ochsenkühn, Thomas ^a   Brand, Stephan ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; ANTICOAGULANT AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; INFLIXIMAB; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 23 RECEPTOR; MERCAPTOPURINE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ABSENCE OF SIDE EFFECTS; ALLERGIC REACTION; ARTHRALGIA; ARTICLE; COHORT ANALYSIS; COLON RESECTION; DEEP VEIN THROMBOSIS; DISEASE ACTIVITY; DISEASE CARRIER; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; ENTERITIS; EPIDIDYMITIS; FACE EDEMA; FEMALE; FLUSHING; GENETIC VARIABILITY; GENOTYPE; HERPES ZOSTER; HOMOZYGOSITY; HOSPITALIZATION; HUMAN; INFLAMMATORY DISEASE; INFUSION; INTESTINE; LEUKOCYTE COUNT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; NAUSEA AND VOMITING; PREDICTOR VARIABLE; PRIORITY JOURNAL; REGRESSION ANALYSIS; REMISSION; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; RISK; RISK ASSESSMENT; SIDE EFFECT; TREATMENT RESPONSE; TUMOR NECROSIS; ULCERATIVE COLITIS; VIRUS INFECTION;

ADULT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; COLECTOMY; COLITIS, ULCERATIVE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL AGENTS; GENETIC VARIATION; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; RECEPTORS, INTERLEUKIN; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77955426386     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.95     Document Type: Article

References (42)

1. Neurath MF. IL-23: a master regulator in Crohn disease. Nat Med2007; 13: 26-28
2. Brand S. Crohn's disease: Th 1, Th 17 or both? The change of a paradigm:new immunological and genetic insights implicate Th 17 cells in the pathogenesisof Crohn's disease. Gut 2009; 58: 1152-1167
3. Fujino S, Andoh A, Bamba S et al. Increased expression of interleukin 17 ininflammatory bowel disease. Gut 2003; 52: 65-70.
4. Seiderer J, Elben I, Diegelmann J et al. Role of the novel Th 17 cytokineIL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17Fexpression in active Crohn's disease and analysis of the IL17F p.His161Argpolymorphism in IBD. Inflamm Bowel Dis 2008; 14: 437-445
5. Brand S, Beigel F, Olszak T et al. IL-22 is increased in active Crohn's diseaseand promotes proinflammatory gene expression and intestinal epithelialcell migration. Am J Physiol Gastrointest Liver Physiol 2006; 290: G827-38.
6. Dambacher J, Beigel F, Zitzmann K et al. The role of the novel Th 17 cytokineIL-26 in intestinal inflammation. Gut 2009; 58: 1207-1217
7. Brand S, Olszak T, Beigel F et al. Cell differentiation dependent expressedCCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting inproliferation and migration of colorectal cancer cells. J Cell Biochem2006; 97: 709-723
8. Bouma G, Strober W. The immunological and genetic basis of inflammatorybowel disease. Nat Rev Immunol 2003; 3: 521-533
9. MacDonald TT, Hutchings P, Choy MY et al. Tumour necrosis factor-alphaand interferon-gamma production measured at the single cell level innormal and inflamed human intestine. Clin Exp Immunol 1990; 81: 301-305
10. Braegger CP, Nicholls S, Murch SH et al. Tumour necrosis factor alpha instool as a marker of intestinal inflammation. Lancet 1992; 339: 89-91.
11. Knight DM, Trinh H, Le J et al. Construction and initial characterization of amouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30: 1443-1453
12. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab forCrohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549
13. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment offistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-1405 (Pubitemid 29205403)
14. Sands BE, Tremaine WJ, Sandborn WJ et al. Infliximab in the treatment ofsevere, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis2001; 7: 83-88
15. Probert CS, Hearing SD, Schreiber S et al. Infliximab in moderately severeglucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut2003; 52: 998-1002.
16. Ochsenkuhn T, Sackmann M, Goke B. Infliximab for acute, not steroidrefractoryulcerative colitis: a randomized pilot study. Eur J GastroenterolHepatol 2004; 16: 1167-1171
17. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction andmaintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476
18. Ferrante M, Vermeire S, Katsanos KH et al. Predictors of early responseto infliximab in patients with ulcerative colitis. Inflamm Bowel Dis2007; 13: 123-128
19. Duerr RH, Taylor KD, Brant SR et al. A genome-wide associationstudy identifies IL23R as an inflammatory bowel disease gene. Science2006; 314: 1461-1463
20. Glas J, Seiderer J, Wetzke M et al. rs1004819 is the main disease-associatedIL23R variant in German Crohn's disease patients: combined analysis ofIL23R, CARD15, and OCTN1/2 variants. PLoS ONE 2007; 2: e819.
21. Glas J, Stallhofer J, Ripke S et al. Novel genetic risk markers for ulcerativecolitis in the chromosome 4q27 region harboring IL2 and IL21 suggest acommon genetic background for ulcerative colitis and celiac disease. Am JGastroenterol 2009; 104: 1737-1744
22. Kobayashi T, Okamoto S, Hisamatsu T et al. IL-23 differentially regulatesthe Th 1/Th 17 balance in ulcerative colitis and Crohn's disease. Gut2008; 57: 1682-1689
23. Cargill M, Schrodi SJ, Chang M et al. A large-scale genetic association studyconfirms IL12B and leads to the identification of IL23R as psoriasis-riskgenes. Am J Hum Genet 2007; 80: 273-290
24. Burton PR, Clayton DG, Cardon LR et al. Association scan of 14,500nonsynonymous SNPs in four diseases identifies autoimmunity variants.Nat Genet 2007; 39: 1329-1337
25. Farago B, Magyari L, Safrany E et al. Functional variants of interleukin-23 receptor gene confer risk for rheumatoid arthritis but not for systemicsclerosis. Ann Rheum Dis 2008; 67: 248-250
26. Hollis-Moffatt JE, Merriman ME, Rodger RA et al. Evidence for associationof an interleukin-23 receptor variant independent of the R381Q variantwith rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1340-1344
27. Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerativecolitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-1845
28. D'Haens G, Sandborn WJ, Feagan BG et al. A review of activity indicesand efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-786
29. Sauerbrei W, Royston P. Building multivariable prognostic and diagnosticmodels: transformation of the predictors by using fractional polynomials.J Roy Statist Soc (Ser A) 1999; 162: 71-94.
30. Sauerbrei W, Royston P. Corrigendum: building multivariable prognosticand diagnostic models: transformation of the predictors by using fractionalpolynomials. J Roy Statist Soc (Ser A) 2002; 162: 399-400.
31. Sauerbrei W, Meier-Hirmer C, Benner A et al. Multivariable regressionmodel building by using fractional polynomials: Description of SAS,STATA and R programs. Comput Stat Data Anal 2006; 50: 3464-3485
32. Hosmer DW, Lemeshow S. Applied Logistic Regression (Wiley Series in Probabilityand Statistics). Wiley-Interscience Publication: Hoboken, NJ, USA, 2000.
33. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practicaland powerful approach to multiple testing. J Roy Statist Soc Ser B(Methodological) 1995; 57: 289-300.
34. Taylor KD, Plevy SE, Yang H et al. ANCA pattern and LTA haplotype relationshipto clinical responses to anti-TNF antibody treatment in Crohn'sdisease. Gastroenterology 2001; 120: 1347-1355
35. Esters N, Vermeire S, Joossens S et al. Serological markers for prediction ofresponse to anti-tumor necrosis factor treatment in Crohn's disease. Am JGastroenterol 2002; 97: 1458-1462
36. Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing shorttermand sustained response to infliximab treatment for Crohn's disease.Aliment Pharmacol Ther 2003; 17: 1451-1457
37. Nurieva R, Yang XO, Martinez G et al. Essential autocrine regulation byIL-21 in the generation of inflammatory T cells. Nature 2007; 448: 480-483
38. Schmechel S, Konrad A, Diegelmann J et al. Linking genetic susceptibilityto Crohn's disease with Th 17 cell function: IL-22 serum levels are increasedin Crohn's disease and correlate with disease activity and IL23R genotypestatus. Inflamm Bowel Dis 2008; 14: 204-212
39. Ferrante M, Vermeire S, Fidder H et al. Long-term outcome aft er infliximabfor refractory ulcerative colitis. J Crohn's Colitis 2008; 2: 219-225
40. Aratari A, Papi C, Clemente V et al. Colectomy rate in acute severe ulcerativecolitis in the infliximab era. Dig Liver Dis 2008; 40: 821-826
41. Jakobovits SL, Jewell DP, Travis SP. Infliximab for the treatment of ulcerativecolitis: outcomes in Oxford from 2000 to 2006. Aliment PharmacolTher 2007; 25: 1055-1060
42. Jarnerot G, Hertervig E, Friis-Liby I et al. Infliximab as rescue therapyin severe to moderately severe ulcerative colitis: a randomized, placebocontrolledstudy. Gastroenterology 2005; 128: 1805-1811